Search

Displaying results 1041 - 1050 of 4207 in total
  1. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that...

  2. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.

  3. Drug

    Potassium bitartrate

    go.drugbank.com/drugs/DB11107
    ApprovedInvestigational

    Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120] … Approved by the FDA as a direct food substance, potassium bitartrate is used as an additive, stabilizer, pH control agent, antimicrobial agent, processing aid, or thickener in various food products [L2732

  4. Drug

    Interferon alfa-2a

    go.drugbank.com/drugs/DB00034
    ApprovedInvestigationalWithdrawn

    An oral form is being developed by Amarillo Biosciences. … This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.

  5. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. … In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801].

  6. Drug

    Guaifenesin

    go.drugbank.com/drugs/DB00874
    ApprovedInvestigationalVet approved

    Guaifenesin possesses a storied history, having been originally formally approved by the US FDA in 1952 and continues to be one of very few - if not perhaps the only drug that is readily available and … After the negotiation between FDA and major manufacturers, a voluntary transition of labels for not using guaifenesin in children under the age of 4 years was endorsed by FDA in 2008 [F4525].

  7. Drug

    Coagulation Factor IX (Recombinant)

    go.drugbank.com/drugs/DB00100
    Approved

    Recombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology. … It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell

  8. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … [A275455,L56096] By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies

  9. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.

  10. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.